Skip to content

13F-HR filed by Consonance Capital Management LP

Consonance Capital Management LP filed this 13F-HR for the quarter ended 2020-03-31, filed 2020-05-15, with 31 holding rows worth $1,342,939,000.

Accession
0001085146-20-001588
Filed
2020-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2020

A holdings report, 31 entries on the cover page, a total value of $1,342,939,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,342,939,000 with VALUE read as thousands by filing date, 13F file number 028-14924. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KARYOPHARM THERAPEUTICS INC48576U106COM7,180,700$137,941,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock1,350,360$128,048,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock6,909,374$100,255,000thousands by filing date
CHEMOCENTRYX INC16383L106COM2,297,779$92,325,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM823,165$80,522,000thousands by filing date
KADMON HLDGS INC48283N106COM15,608,948$65,401,000thousands by filing date
OMEROS CORP682143102COM4,479,872$59,896,000thousands by filing date
CAREDX INC14167L103COM2,660,716$58,083,000thousands by filing date
AKEBIA THERAPEUTICS INC00972D105COMMON STOCK7,121,283$53,979,000thousands by filing date
EPIZYME INC29428V104COM3,304,918$51,259,000thousands by filing date
UNIQURE NVN90064101SHS1,032,636$48,999,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM3,175,535$47,093,000thousands by filing date
PRINCIPIA BIOPHARMA INC74257L108COM689,718$40,955,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW3,432,232$40,466,000thousands by filing date
AXOGEN INC05463X106COM3,566,054$37,087,000thousands by filing date
KINIKSA PHARMACEUTICALS LTDG5269C101COM CL A2,240,779$34,687,000thousands by filing date
APTOSE BIOSCIENCES INC COM03835T200Stock5,796,482$34,431,000thousands by filing date
RETROPHIN INC761299106COM2,314,421$33,767,000thousands by filing date
COHERUS ONCOLOGY INC19249H103COM2,020,002$32,764,000thousands by filing date
KRYSTAL BIOTECH INC COM501147102Stock654,586$28,304,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK1,654,600$25,431,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock1,979,669$22,449,000thousands by filing date
LIMINAL BIOSCIENCES INC53272L103COM3,287,311$21,980,000thousands by filing date
BELLUS HEALTH INC NEW07987C204COM1,597,503$15,943,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS1,244,460$11,524,000thousands by filing date
IVERIC BIO INC46583P102COM3,150,565$10,838,000thousands by filing date
ADMA BIOLOGICS INC000899104COM3,383,290$9,744,000thousands by filing date
AXOVANT SCIENCES LTDG0750W203COM3,653,303$8,914,000thousands by filing date
OVID THERAPEUTICS INC690469101COMMON STOCK2,580,878$7,691,000thousands by filing date
BIOTELEMETRY INC090672106COM49,219$1,895,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM10,000$268,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-20-001588this filing2020-05-15acceptance time not in the bulk data set